FF-10158 is under clinical development by Advanced Accelerator Applications and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase I drugs for Adenocarcinoma Of The Gastroesophageal Junction have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FF-10158’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FF-10158 overview

177LuFF-10158 is under development for the treatment of recurrent glioblastoma multiforme, pancreatic ductal adenocarcinoma and gastroesophageal adenocarcinoma. The drug candidate comprises of FF-10158 radiolabelled with lutetium 177-labeled isotope. It is a radio conjugate that acts by targeting integrin alpha V (ITGAV), integrin beta 3 (ITGB3) and integrin beta 5 (ITGB5). It is administered through parenteral route.

Advanced Accelerator Applications overview

Advanced Accelerator Applications (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company develops new medicines which targets the orphan diseases in the field of cardiology, oncology, neurology and inflammation. The company is also involved in manufacturing Positron Emission tomography (PET) and single-photon emission computed tomography (SPECT). It’s key brand portfolio comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnascan, Fluorochol, AAACholine, Cholscan, Lysakare, Dopaview, Padoview and Lumark. AAA is headquartered in Rueil-Malmaison Cedex, Ile-de-France, France.

For a complete picture of FF-10158’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.